Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Circulation Research. 2008;103:450-453
Published online before print July 24, 2008, doi: 10.1161/CIRCRESAHA.108.179861
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
103/5/450    most recent
CIRCRESAHA.108.179861v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mansouri, R. M.
Right arrow Articles by Fruchart, J.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mansouri, R. M.
Right arrow Articles by Fruchart, J.-C.
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Animal models of human disease
Right arrow Risk Factors
Right arrow Gene regulation
Right arrow Genetically altered mice
Right arrow Lipid and lipoprotein metabolism
Right arrow Mechanism of atherosclerosis/growth factors
(Circulation Research. 2008;103:450.)
© 2008 American Heart Association, Inc.

Report

Atheroprotective Effect of Human Apolipoprotein A5 in a Mouse Model of Mixed Dyslipidemia

Roxane M. Mansouri, Eric Baugé, Philippe Gervois, Jamila Fruchart-Najib, Catherine Fiévet, Bart Staels, Jean-Charles Fruchart

From the Institut Pasteur de Lille, Inserm U545, Faculté des Sciences Pharmaceutiques et Biologiques, Université de Lille 2, France.

Correspondence to Bart Staels, Inserm, U545, Institut Pasteur de Lille, Lille F-59019, France. E-mail bart.staels{at}pasteur-lille.fr

Hypertriglyceridemia is an independent risk factor for coronary artery disease. Because apolipoprotein (Apo)A5 regulates plasma triglyceride levels, we investigated the impact of human (h)ApoA5 on atherogenesis. The influence of hApoA5 transgenic expression was studied in the ApoE2 knock-in mouse model of mixed dyslipidemia. Our results demonstrate that hApoA5 lowers plasma triglyceride levels in Western diet–fed ApoE2 knock-in mice. Moreover, atherosclerotic lesion development was significantly decreased in the hApoA5 transgenic mice. Finally, pharmacologic activation of hApoA5 expression by the peroxisome proliferator-activated receptor-{alpha} agonist fenofibrate resulted in an enhanced atheroprotection. These results identify an atheroprotective role of hApoA5 in a mouse model of mixed dyslipidemia.


Key Words: human apolipoprotein A5 • atherosclerosis • dyslipidemia • fibrates • mouse model




This article has been cited by other articles:


Home page
 J. Lipid Res.Home page
T. M. Forte, X. Shu, and R. O. Ryan
The ins (cell) and outs (plasma) of apolipoprotein A-V
J. Lipid Res., April 1, 2009; 50(Supplement): S150 - S155.
[Abstract] [Full Text] [PDF]


Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.